Molecular and Nanoscale Physics Group, School of Physics and Astronomy, University of Leeds, Leeds LS2 9JT, United Kingdom.
J Phys Chem B. 2023 Mar 23;127(11):2466-2474. doi: 10.1021/acs.jpcb.2c07256. Epub 2023 Mar 14.
Lipid-shelled microbubbles (MBs) offer potential as theranostic agents, capable of providing both contrast enhancement in ultrasound imaging as well as a route for triggered drug release and improved localized drug delivery. A common motif in the design of such therapeutic vehicles is the attachment of the drug carrier, often in the form of liposomes, to the microbubble. Traditionally, such attachments have been based around biotin-streptavidin and maleimide-PDP chemistries. Comparatively, the use of DNA-lipid tethers offers potential advantage. First, their specificity permits the construction of more complex architectures that might include bespoke combinations of different drug-loaded liposomes and/or targeting groups, such as affimers or antibodies. Second, the use of dual-lipid tether strategies should increase the strength of the individual tethers tethering the liposomes to the bubbles. The ability of cholesterol-DNA (cDNA) tethers for conjugation of liposomes to supported lipid bilayers has previously been demonstrated. For in vivo applications, bubbles and liposomes often contain a proportion of polyethylene glycol (PEG) to promote stealth-like properties and increase lifetimes. However, the associated steric effects may hinder tethering of the drug payload. We show that while the presence of PEG reduced the tethering affinity, cDNA can still be used for the attachment of liposomes to a supported lipid bilayer (SLB) as measured via QCM-D. Importantly, we show, for the first time, that QCM-D can be used to study the tethering of microbubbles to SLBs using cDNA, signified by a decrease in the magnitude of the frequency shift compared to liposomes alone due to the reduced density of the MBs. We then replicate this tethering interaction in the bulk and observe attachment of liposomes to the shell of a central MB and hence formation of a model therapeutic microbubble.
脂质壳微泡(MB)作为治疗剂具有潜力,能够在超声成像中提供对比增强,以及触发药物释放和改善局部药物输送的途径。此类治疗载体设计的常见主题是将药物载体(通常以脂质体的形式)连接到微泡上。传统上,这种连接基于生物素-链霉亲和素和马来酰亚胺-PDP 化学。相比之下,使用 DNA-脂质系链具有潜在优势。首先,它们的特异性允许构建更复杂的结构,其中可能包括不同载药脂质体和/或靶向基团(如适配体或抗体)的定制组合。其次,使用双脂质系链策略应该会增加将脂质体系链到气泡的各个系链的强度。先前已经证明胆固醇-DNA(cDNA)系链能够将脂质体连接到支撑脂质双层上。对于体内应用,气泡和脂质体通常含有一定比例的聚乙二醇(PEG)以促进类似隐身的特性并延长寿命。然而,相关的空间位阻效应可能会阻碍药物有效负载的系链。我们表明,虽然 PEG 的存在降低了系链亲和力,但 cDNA 仍可用于通过 QCM-D 测量将脂质体连接到支撑脂质双层(SLB)。重要的是,我们首次表明,QCM-D 可用于使用 cDNA 研究微泡与 SLB 的系链,与单独的脂质体相比,由于 MB 的密度降低,频率位移的幅度减小,这表明了系链。然后,我们在本体中复制这种系链相互作用,并观察到脂质体附着在中央 MB 的壳上,从而形成了模型治疗性微泡。